Dyslipidemia plays a crucial role in the development and progression of atherosclerosis. Current guidelines focus on lowering low-density lipoprotein cholesterol (LDL-C), with statins being the most effective agents. However, statins are insufficient for primary or secondary prevention of acute myocardial infarction. Emerging therapies, including genetic therapies and RNA-based therapies, are being explored to improve cardiovascular outcomes. Nanotechnology also offers new possibilities for drug delivery, enhancing the effectiveness and safety of medications. This narrative review summarizes current and emerging therapies for managing dyslipidemia, including statins, PCSK9 inhibitors, ezetimibe, bempedoic acid, and other lipid-lowering drugs. The review highlights the benefits and limitations of these therapies, emphasizing the importance of individualized treatment based on patient-specific factors.Dyslipidemia plays a crucial role in the development and progression of atherosclerosis. Current guidelines focus on lowering low-density lipoprotein cholesterol (LDL-C), with statins being the most effective agents. However, statins are insufficient for primary or secondary prevention of acute myocardial infarction. Emerging therapies, including genetic therapies and RNA-based therapies, are being explored to improve cardiovascular outcomes. Nanotechnology also offers new possibilities for drug delivery, enhancing the effectiveness and safety of medications. This narrative review summarizes current and emerging therapies for managing dyslipidemia, including statins, PCSK9 inhibitors, ezetimibe, bempedoic acid, and other lipid-lowering drugs. The review highlights the benefits and limitations of these therapies, emphasizing the importance of individualized treatment based on patient-specific factors.